Xenome in third screening partnership
Wednesday, 27 March, 2002
Brisbane biotech and animal venom specialist Xenome Ltd has found yet another partner to screen its library of bioactive peptide molecules.
Its latest agreement, the third signed in less than a month, is with Icagen Inc, a private US company focused on ion channel therapeutics.
Xenome molecules based on structures isolated from venomous species will be screened against the North Carolina company's proprietary ion channel drug targets.
The new partnership is broader in scope than an earlier agreement Xenome negotiated with another ion channel specialist, UK-based Ionix Pharmaceuticals.
Channels regulating the flow of ions in cells are crucial to the development of many diseases.
Xenome has also struck an agreement to test its molecules against Melbourne-based Cytopia Ltd's anti-inflammatory and anti-cancer targets.
The latest collaboration, like the others, will see the partners sharing equally in any IP and commercial rewards which flow from the joint venture.
The various agreements contain exclusive and non-exclusive clauses which have been structured to avoid any conflicts of interest, according to Xenome CEO Tony Evans.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
